Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT02306850 |
| Title | Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma |
| Acronym | NeoPembroMel |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | St. Louis University |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA |